Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
Journal: British journal of haematology
Published: July 02, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 09, 2026
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.
Journal: The Lancet. Haematology
Published: November 17, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.
Journal: Leukemia & lymphoma
Published: July 09, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid Disorders.
Journal: The Journal of molecular diagnostics : JMD
Published: January 28, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.
Journal: Clinical trials (London, England)
Published: January 16, 2025
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 28, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Journal: The New England journal of medicine
Published: October 16, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Journal: The New England journal of medicine
Published: July 24, 2024
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Journal: Blood
Published: May 20, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: April 21, 2024
Last Updated: 09/26/2026